Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Year: 2024
Type: erratum
Source: Nature Medicine
Authors: Steven M. Horwitz, Ajit J. Nirmal, Jahan Rahman, Ran Xu, Esther Drill, Natasha Galasso, Nivetha Ganesan, Theresa Davey, Helen Hancock, Leslie Perez, Catherine Maccaro, Alexandra Bahgat, Evan Marzouk, Elizabeth Cathcart, Alison Moskowitz, Ariela Noy, Anita Kumar, Eric Jacobsen, David C. Fisher, Neha Mehta-Shah, Youn H. Kim, Michael Khodadoust, Nikita Kotlov, Anastasia Nikitina, Olga Kudryashova, Valeria Zubareva, Ksenia Zornikova, Nara Shin, Maria Sorokina, Sandrine Degryse, Ekaterina Postovalova, Aleksander Bagaev, Kinga Hosszu, Devin McAvoy, Jaap J. Boelens, Wenchao Wu, Zoe Ciantra, Jackson W. Appelt, Christopher Trevisani, Sam Amaka, David M. Weinstock, Santosha A. Vardhana
Institutions: Memorial Sloan Kettering Cancer Center, NewYork–Presbyterian Hospital, Dana-Farber Cancer Institute, Washington University in St. Louis, Stanford University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404394134